RT Journal Article
SR Electronic
T1 Sub-national forecasts of COVID-19 vaccine acceptance across the UK: a large-scale cross-sectional spatial modelling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.17.20248382
DO 10.1101/2020.12.17.20248382
A1 A. de Figueiredo
YR 2020
UL http://medrxiv.org/content/early/2020/12/18/2020.12.17.20248382.abstract
AB Introduction There is evidence of decreasing uptake of routine immunisations in the UK in recent years. As the United Kingdom begins a mass vaccination campaign with a novel COVID-19 vaccine, it is unclear whether refusal of the vaccine in some regions and among some socio-economic groups will pose challenges for achieving herd/community immunity against SARS-CoV-2.Methods This study estimates uptake of a COVID-19 at unprecedented spatial resolution across the UK using a large-scale survey and state-of-the-art Bayesian statistical methods for estimating public opinion. Between 24 September and 14 October 2020, 17,684 individuals are surveyed in a cross-sectional online survey design. Regions and socio-economic groups who may be more resistant towards a new vaccine are identified using multilevel regression and poststratification. Gibbs sampling is used for Bayesian model inference, with uncertainty in parameter estimates captured via 95% highest posterior density intervals.Findings This study predicts that clusters of non-vaccinators will likely emerge in many regions across the UK, most notably in London (which has 13 of the 20 lowest ranking regions) and the North West (which has four, including Greater Manchester and Liverpool). Males are much more likely to state intent to accept the vaccine than females (OR 1·59, 1·47 to 1·73); while Muslims are less likely than atheists / agnostics (0·75, 0·57 to 0·96), Black / Black British are less likely than Whites (0·47, 0·38 to 0·60), and Polish speakers (0·45, 0·31 to 0·63) are less likely than those who primarily speak English or Welsh. Across the UK, 8·7% (8·2 to 9·2%) state that they would “definitely not” accept a vaccine, but less than half (47·5%, 46·5 to 48·5%) say they would “definitely” accept a COVID-19 vaccine, with a substantial proportion unsure.Interpretation The study findings are extremely important in the context of achieving herd/community immunity. Low predicted acceptance rates in parts of London and the North West are of particular concern as many of these regions have among the highest rates of COVID-19 infection across the UK: low vaccine uptake in these regions may result in disease “hotspots” that amplify the spread of the disease and require increases in vaccination levels in adjacent regions to provide nationwide herd/community immunity. It is therefore extremely important to identify such regions, and to engage with communities within them in advance of vaccination rollout to the population at large. Encouragingly, intent to accept a COVID-19 vaccine is higher among older age-groups, who are among the first to receive a COVID-19 vaccine.Declaration of Interests The Author is involved in Vaccine Confidence Project collaborative grants with GlaxoSmithKline outside the submitted work.Funding This project was funded by the Imperial College COVID-19 Response Fund.Ethical Approval Approval for this study was obtained via the Imperial College Research Ethics Committee on 24 July 2020 with reference 20IC6133.Competing Interest StatementThe Author is involved in Vaccine Confidence Project collaborative grants with GlaxoSmithKline outside the submitted work.Funding StatementThis project was funded by the Imperial College COVID-19 Response Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for this study was obtained via the Imperial College Research Ethics Committee on 24 July 2020 with reference 20IC6133.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this study are not currently publicly available. The Author intends to make the data open access in early 2021.